On Friday, Guggenheim maintained a Buy rating on Zura Bio Ltd. (NASDAQ:ZURA) with a consistent price target of $15.00. The firm's analysis follows Zura Bio's third-quarter earnings release and discussions with the company's management team. Key points include the progress of Zura Bio's clinical programs, especially tibulizumab for systemic sclerosis and plans for upcoming studies in hidradenitis suppurativa.
Zura Bio is preparing to launch a Phase II clinical trial for its drug candidate tibulizumab, aimed at treating systemic sclerosis, with a study population of around 80 participants. The initiation of this trial is expected in the fourth quarter of 2024, with enrollment completion anticipated in the first quarter of 2026. The company plans to have the study results ready by the fourth quarter of 2026.
For the treatment of hidradenitis suppurativa, Zura Bio intends to submit an Investigational New Drug (IND) application in the first quarter of 2025. The Phase II trial, which may involve 120 to 180 participants, is slated to begin in the second quarter of 2025. The inclusion of approximately 30% of patients who have experience with TNF inhibitors is a strategic move to address the unmet needs within this patient population. Results from this study are expected in the second half of 2026.
While there have been no new developments regarding Zura Bio's other drug candidates, crebankitug and torukimab, the company continues to observe the data released on external IL-7Rα and IL-33/ST2 inhibitors. The firm highlights a near-term catalyst for Zura Bio's shares, which could come from the potential success of QTTB's bempikibart in Phase II trials for atopic dermatitis and alopecia areata, expected in December.
Guggenheim's positive outlook is further supported by Zura Bio's financial position, with the company reportedly holding around $188 million in cash, which is considered a robust capitalization for its ongoing and planned activities. The firm reiterates its Buy rating and $15 price target, indicating confidence in Zura Bio's potential and strategy.
In other recent news, Zura Bio Ltd reported robust first-quarter results for 2024, ending with a cash balance of $89.8 million following a successful funding round that raised about $112 million. The company also disclosed positive clinical trial results for lusvertikimab, a drug under investigation for treating moderate-to-severe ulcerative colitis, which has reinforced the bullish outlook of Piper Sandler on Zura Bio's stock. In addition, Leerink Partners initiated coverage of Zura Bio with an Outperform rating and a $15 price target, highlighting the company's strong portfolio of immunology assets.
Zura Bio recently issued pre-funded warrants to shareholders who surrendered 4 million Class A ordinary shares back to the company at no cost; these shares were immediately canceled and retired. At the company's Annual General Meeting, all nine director nominees were re-elected to the board, and the reappointment of WithumSmith+Brown, PC as the independent registered public accounting firm was ratified.
InvestingPro Insights
Zura Bio Ltd.'s financial landscape offers some interesting perspectives that complement Guggenheim's analysis. According to InvestingPro data, the company's market capitalization stands at $285.07 million, which is relatively modest compared to its cash position of $188 million mentioned in the article. This substantial cash reserve is further highlighted by an InvestingPro Tip indicating that Zura "holds more cash than debt on its balance sheet," aligning with the article's emphasis on the company's robust capitalization for its clinical programs.
The company's stock has shown a strong return over the last three months, with InvestingPro data reporting a 26.27% price total return. This positive momentum could be reflective of investor optimism surrounding Zura's clinical progress and upcoming catalysts, as discussed in the article.
However, it's important to note that Zura Bio is not currently profitable, as pointed out by another InvestingPro Tip. This is consistent with the company's focus on research and development in its pre-revenue stage, which is common for biotech firms advancing clinical programs.
For investors seeking a more comprehensive analysis, InvestingPro offers 6 additional tips for Zura Bio, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.